Trial Profile

An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NEO-PV 01 (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
Indications Bladder cancer; Carcinoma; Malignant melanoma; Non-small cell lung cancer; Transitional cell carcinoma
Focus Adverse reactions
Sponsors BioNTech; Neon Therapeutics

Most Recent Events

10 Jun 2020 Status changed from active, no longer recruiting to completed.
08 Nov 2019 According to a Neon Therapeutics media release, updated results (n=82, August 2019 data cut) from the trial were presented at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting in National Harbor, MD
08 Nov 2019 Results presented in the Neon Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com